EVO vs. GPCR, CPRX, HRMY, AGIO, GLPG, SDGR, SUPN, NAMS, SNDX, and EWTX
Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Structure Therapeutics (GPCR), Catalyst Pharmaceuticals (CPRX), Harmony Biosciences (HRMY), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), Schrödinger (SDGR), Supernus Pharmaceuticals (SUPN), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical preparations" industry.
Structure Therapeutics (NASDAQ:GPCR) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
Structure Therapeutics presently has a consensus price target of $85.71, indicating a potential upside of 137.11%. Evotec has a consensus price target of $11.00, indicating a potential upside of 109.52%. Given Evotec's higher possible upside, equities analysts plainly believe Structure Therapeutics is more favorable than Evotec.
Structure Therapeutics has higher earnings, but lower revenue than Evotec.
In the previous week, Structure Therapeutics and Structure Therapeutics both had 4 articles in the media. Structure Therapeutics' average media sentiment score of 0.83 beat Evotec's score of 0.68 indicating that Evotec is being referred to more favorably in the news media.
Structure Therapeutics received 12 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 78.95% of users gave Structure Therapeutics an outperform vote while only 75.00% of users gave Evotec an outperform vote.
91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Structure Therapeutics' return on equity of 0.00% beat Evotec's return on equity.
Summary
Structure Therapeutics beats Evotec on 6 of the 11 factors compared between the two stocks.
Get Evotec News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
